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Musculoskeletalsymptomsincludingarthralgiaandmyalgiaoccurfrequentlyinagingwomen,particularlyduringthetransitionto
menopause, when plasma estrogens precipitously decline. In postmenopausal women (PMW)with breast cancer, third-generation
aromatase inhibitors (AIs) as adjuvant hormonal therapy have proven to be more eﬀective, and to have a more predictable side
eﬀect proﬁle, than tamoxifen. However, AIs further reduce plasma estrogens in PMW, exacerbating musculoskeletal symptoms.
Clinical trial data have shown signiﬁcantly higher incidences of arthralgia and myalgia with AIs compared with women on
tamoxifen or placebo. Symptoms may be severe enough to signiﬁcantly aﬀect quality of life; musculoskeletal symptoms are a
frequent reason for discontinuing therapy. In many cases, symptoms can be eﬀectively managed with oral analgesics or other
strategies. Early recognition and eﬀective management of musculoskeletal symptoms can help maximize treatment compliance,
enabling patients to derive optimal beneﬁt from therapy in terms of preventing recurrence.
1.Introduction
The third-generation aromatase inhibitors (AIs) have proven
superior to tamoxifen when used as adjuvant hormonal
therapy in postmenopausal women with hormone recep-
tor positive (HR+) early breast cancer. Major trials have
established that AIs improve disease-free survival (DFS)
when used either as initial adjuvant therapy or as a
switch/sequential option for patients completing 2 or more
years of prior tamoxifen treatment [1–4], and the use of AIs
as adjuvant endocrine therapy for postmenopausal women
with HR+ breast cancer has been steadily increasing [5]. AIs
arealsoanattractivealternativetotamoxifenbecauseoftheir
adverse event (AE) proﬁle, which closely mimics symptoms
commonly associated with the menopause-related decline in
estrogen level while lacking the rare, yet serious, AEs asso-
ciated with tamoxifen (e.g., endometrial cancer and venous
thromboembolism) [6]. The safety of adjuvant anastrozole,
letrozole, and exemestane has been established in major
clinical studies including the arimidex tamoxifen alone or
in combination (ATAC) trial, the breast international group
1-98 (BIG 1-98) trial, and the intergroup exemestane study
(IES),respectively[3,4,7,8].Whilethesetrialsdiﬀerinstudy
design, patient population, and AE reporting criteria, they
have generally shown similar safety proﬁles, with a predom-
inance of mild-to-moderate menopause-related symptoms
such as loss of bone density, musculoskeletal symptoms
such as arthralgias, myalgias, and hot ﬂashes. Arthralgias
and myalgias in particular are among the most commonly
reported musculoskeletal AEs [9–11] and are an important
cause of treatment discontinuation [11, 12]. In this paper,
we examine the incidence of musculoskeletal side eﬀects
with the diﬀerent AIs, with an emphasis on reducing and
managing these AEs in postmenopausal women receiving
adjuvant AI therapy.
2.The Syndrome of AI-AssociatedArthralgia
andMyalgia
While the clinical presentation may vary considerably,
arthralgia typically includes symmetrical pain or stiﬀness in
the joints that is not associated with inﬂammatory processes
and the joint destruction of arthritis [13]. Soreness in the
hands, knees, hips, lower back, shoulders and/or feet, early
morningstiﬀness,anddiﬃcultysleepingmaybepresent,and2 Journal of Oncology
patients may experience symptoms such as rings not ﬁtting
as they once did, because of mild thickening of soft tissues
[13]. Symptoms of arthralgia and myalgia may also include
an impaired ability to completely close or stretch the hand
and/or ﬁngers and diﬃculty performing daily activities such
asdressing,driving,ortyping[14].Anothercuesuggestiveof
arthralgia is patients’ “feeling like they have aged suddenly”
upon squeezing or ﬂexing the aﬀected joints [13]. A recent
prospective study evaluating changes in the hands and wrists
of patients taking AIs (N = 12) or tamoxifen (N = 5)
found that after 6 months, AI users were >2-fold more likely
to have decreased grip strength compared with tamoxifen
users (relative risk [RR], 2.08), and >3.5 times more likely
than tamoxifen users to have magnetic resonance imaging
(MRI)-assessed worsening of tenosynovial changes (RR,
3.67) [15]. Worsening of tenosynovial changes was found
to be strongly related to a higher decrease in grip strength
(Spearman correlation, −0.64; P = .0074). These ﬁndings
suggest that AI users are more likely than tamoxifen users to
have new-onset or worsening of preexisting musculoskeletal
symptoms, and that these symptoms could be correlated
with functional impairment and objectively assessed MRI
changes [15]. Another recent study examined AI-related
arthralgia in women receiving AIs (n = 92) and a control
group not receiving hormonal therapy (n = 28) [16].
Investigators found a 33% incidence of AI-related new-
onset or worsening arthralgia; the most commonly aﬀected
joints were the knee (70%), wrist (70%), and small joints
in the hand (63%). Patients receiving AIs with arthralgia
had more joint and tendon eﬀusions (69% versus 42%; P<
.05) and electrophysiologic ﬁndings consistent with carpal
tunnel syndrome (46% versus 20%; P<. 05) compared
to those without arthralgia, and those receiving AIs had
thicker tendons compared to those never receiving AIs
(P<. 001) [16]. However, there was no evidence of an
autoimmune or inﬂammatory process associated with AI
use, and the authors acknowledged that some patients with
AI-related arthralgia had no evidence of tenosynovial or
electrophysiologic changes; the latter ﬁndings would seem to
precludeastraightforwardassociationbetweenthesechanges
and the symptoms of arthralgia in patients taking AIs.
3. Risk Factors
Menopausal status appears to be an important risk factor
for musculoskeletal symptoms in women. In a study of the
natural history of menopausal symptoms in women aged
40−55 years (N = 237), joint/muscle pain was reported
by over half (57%) [17]. About one third (28.7%) of the
women were perimenopausal, and these women showed the
highest incidence of joint/muscle pain (67.6%) compared
with pre- (54%) or postmenopausal women (48.8%) [17].
Another community-based study of healthy women found
that postmenopausal women (n = 263), compared with
premenopausal (n = 734) or perimenopausal women
(n = 363), experienced a signiﬁcantly higher incidence of
arthralgia (38.6% versus 29.8% versus 35.2%, resp.; P =
.028) [18]. This study also found that postmenopausal
Table 1: Arimidex tamoxifen alone or in combination trial. (a)
Percent of patients with joint symptoms, and odds ratio (OR)
for joint symptoms, in the population of patients without joint
symptoms at study entry. (b) Signiﬁcant predictive factors for joint
symptoms from multivariate analysis in the population of patients
without joint symptoms at study entry [20].
(a)
Anastrozole
N = 2,698
Tamoxifen
N = 2,735 OR (95% CI)
Overall 35.2% 30.3% 1.25
(1.11–1.40)
Mild 19.2% 17.3% 1.14
(0.99–1.31)
Moderate 13.6% 10.8% 1.29
(1.09–1.53)
Severe 2.4% 2.2% 1.06
(0.73–1.54)
(b)
OR (95% CI) P Value
Anastrozole versus tamoxifen 1.26
(1.12–1.42) <. 0001
Previous hormone replacement
therapy versus none
1.53
(1.35–1.74) <. 0001
Chemotherapy versus none 1.24
(1.07–1.43) .004
Hormone receptor status
Negative versus positive 0.78
(0.62–0.98)a .03
Unknown versus positive 0.76
(0.59–0.97)a .028
Region
UK versus rest of world 1.20
(1.02–1.40) .025
North America versus rest of world 2.09
(1.79–2.43) <.0001
Body mass index > 30 1.33
(1.14–1.55) <.0001
a Negative predictor.
CI: conﬁdence interval
women had signiﬁcantly lower scores on multiple measures
of a quality of life (QoL) questionnaire (Short Form 36)
compared with premenopausal women [18]. Another study,
in Sweden, found that shoulder, arm, leg, and/or back
pain was more common in women than in men among
individuals between 20 and 64 years of age [19]. This
study also showed that the percent of female subjects with
musculoskeletal pain increased with increasing body mass
index (BMI) and decreased with increasing physical activity.
These ﬁndings highlight the importance of menopausal
status, weight, and physical activity on the risk for arthralgia
in women.
Risk factors for joint symptoms were examined in
patients with breast cancer enrolled in the ATAC trial,
which compared initial adjuvant treatment with anastrozole
relative to tamoxifen. Only women who did not reportJournal of Oncology 3
Table 2: Incidence of arthralgia and myalgia in postmenopausal women with early breast cancer as reported from phase III trials of third-
generation aromatase inhibitors in the adjuvant setting.
Phase 3 trial Median followup (months) Arthralgia (%) Myalgia (%)
ATAC [1] 68 35.6% ANA versus 29.4% TAMa;P<. 0001 NR
BIG 1-98 [2] 25.8 20.3% LET versus 12.3% TAMb;P<. 001 6.4% LET versus 6.1% TAM; P =.61
BIG 1-98 [8] 51 20.0% LET versus 13.5% TAM; P< . 001 7.1% LET versus 6.1% TAM; P = .19
TEAM [21] 33 17.9% EXE versus 9.2% TAM; P<. 001 NR
IES [3] 55.7 20.8% EXE versus 15.1% TAMb; P<. 0001 25.7% EXE versus 20.3% TAMc; P<. 0001
A B C S G8 / A R N O9 5[ 22] 28 19% ANA versus 16% TAMd; P = .0546 NR
ARNO 95 [23] 30.1 11.7% ANA versus 4.9% TAMe NR
MA.17 [24] 30 25% LET versus 21% PLAb; P<. 001 15% LET versus 12% PLA; P = .004
ABCSG:austrianbreastandcolorectalcancerstudygroup;ANA:anastrozole;ARNO:arimidex-nolvadex;ATAC:arimidextamoxifenaloneorincombination;
BIG: breast international group; EXE: exemestane; IES: intergroup exemestane study; LET: letrozole; PLA: placebo; TAM: tamoxifen; TEAM: tamoxifen
exemestane adjuvant multicenter; NR: not reported.
aGrade not speciﬁed.
bAll grades.
joint symptoms at randomization were included in the
analysis (anastrozole, n = 2,698; tamoxifen, n = 2,735),
so as to evaluate new-onset (and likely treatment-related)
joint symptoms [20]. The results showed higher overall
joint symptoms in the anastrozole-treated group versus the
tamoxifen-treated group (35.2% versus 30.3%, resp.; odds
ratio [OR], 1.25; 95% conﬁdence interval [CI], 1.11–1.40),
with a similar distribution of severity between the groups
(Table 1(a)).Themajorityofadditionaljointsymptomswith
anastrozole occurred during the ﬁrst 2 years of treatment.
Signiﬁcant risk factors for joint symptoms from multivariate
analysisincludedprioruseofhormone-replacementtherapy,
prior chemotherapy, geographic region (higher in North
America, lower in the United Kingdom), BMI >30, and
positive hormone receptor status (Table 1(b)) [20]. The
investigators noted that all of these factors are potentially
linked with a greater decline in estrogen levels at the time
of initiation of endocrine treatment.
4.Efﬁcacy andJoint Symptoms in
Adjuvant AI Trials
4.1. AIs Versus Tamoxifen. Comparative studies have gen-
erally reported a higher incidence of both arthralgia and
myalgia with AIs versus tamoxifen [2, 3, 21, 22, 25]( Table 2),
although it should be remembered that AEs were not neces-
sarily deﬁned homogeneously between trials. Initial adjuvant
therapy with AIs has been examined in the ATAC, BIG 1-98,
and Tamoxifen Exemestane Adjuvant Multicenter (TEAM)
trials. In terms of eﬃcacy, both anastrozole and letrozole
improved DFS over tamoxifen in patients with HR+ disease,
whereas a signiﬁcant beneﬁt of exemestane in this setting has
not yet been demonstrated [21]. It has been postulated that
the near-complete suppression of estrogen levels achieved
with the third-generation AIs relative to tamoxifen, ovarian
ablation, or second-generation AIs may be one reason for
an increased frequency of arthralgia/myalgia with AIs [26,
27]. Indeed, recent retrospective data from the ATAC trial
suggestthatjointsymptomsinpatientsonendocrinetherapy
may be an important indicator of eﬃcacy, as they are
related to signiﬁcant estrogen suppression with anastrozole.
It was shown that the risk of breast cancer recurrence was
lower in women with joint symptoms (hazard ratio [HR],
0.60; P<. 0001) relative to those without joint symptoms
[28]. These results held true regardless of treatment group.
For anastrozole-treated patients with joint symptoms at 3
months, the HR was 0.65 (P = .001), and for tamoxifen-
treated patients, the HR was 0.58 (P<. 0001) [28]. These
ﬁndings suggest that the emergence of joint symptoms with
either AIs or tamoxifen could be an important predictor for
lower recurrence risk. COSTART-deﬁned joint symptoms,
including arthralgia, arthritis, arthrosis, and joint disorder
were reported by signiﬁcantly more anastrozole-treated
patients in the ATAC study at 68 months’ followup (Table 2)
[1]. Nearly half (46%) of patients reporting joint symptoms
in ATAC, however, reported them as an exacerbation of
preexisting conditions [29]. Most events (68% anastrozole
and 59% tamoxifen) occurred within the ﬁrst 24 months
of therapy, and the peak occurrence was at 6 months
(29% and 20%, resp.). Importantly, half of the patients
whose joint symptoms resolved were symptom-free within 6
months, and 75% were free of symptoms within 18 months.
Sixty percent received treatment for joint symptoms, with
>90% of these patients managing their joint symptoms with
nonsteroidal anti-inﬂammatory drugs (NSAIDs) alone or in
combination with other analgesics. Serious joint symptoms
were similar between the groups (10.6% versus 10.4%), and
joint symptoms were rarely a cause of treatment withdrawal
(2.1% versus 0.9%) [29]. The pathogenesis of carpal tunnel
syndrome and its potential association with AI use is not
fully understood, but hormonal factors may play a role, in
view of its association with pregnancy and menopause, and
its predominance in women [16, 30]. In the ATAC study,
there was a signiﬁcantly higher incidence of carpal tunnel
syndrome with anastrozole versus tamoxifen, but the overall
incidence was low (3% versus 1%; P<. 0001) [25]. Initial
adjuvant therapy with letrozole has also been associated
with a higher incidence of joint symptoms compared with
tamoxifen. The BIG 1-98 trial reported a signiﬁcantly
higher incidence of arthralgia, although the incidence of4 Journal of Oncology
myalgia was not diﬀerent between groups (Table 2)[ 2]. Most
reported arthralgias and myalgias in both treatment groups
in BIG 1-98 were grade 1 or 2. The incidence of carpal tunnel
syndrome has not been reported in BIG 1-98.
An increased incidence of arthralgia and myalgia is not
limited to the use of nonsteroidal AIs. Patients receiving
the steroidal AI exemestane in the TEAM trial had a
signiﬁcantly higher incidence of arthralgia compared with
those receiving tamoxifen (Table 2). A subanalysis from the
TEAM trial also showed that, at 12 months, patients treated
with exemestane (n = 808) had a signiﬁcantly higher
incidence of bone/muscle aches than did patients treated
withtamoxifen(n = 806)(77%versus70%,resp.;P<. 0001)
[31]. More than 60% of women reported mild, moderate,
or severe bone and/or muscle aches at the time of study
entry. In the IES, patients who switched to exemestane after
2−3 years of tamoxifen also had both a higher incidence of
arthralgia (Table 2) and also carpal tunnel syndrome (2.8%
versus 0.4%, resp.; P<. 0001) compared with patients who
remained on tamoxifen [3]. Switching to an AI following
2 years of prior tamoxifen treatment was also associated
with an increase in arthralgia/bone pain in the Arimidex-
Nolvadex 95 study (N = 979); more patients who switched
to anastrozole from tamoxifen reported this symptom than
did those continued on tamoxifen (Table 2)[ 23]. Higher
rates of arthralgia/myalgia have also been seen in the
extended adjuvant setting in postmenopausal women who
have already received 5 years of prior adjuvant tamoxifen.
In the extended adjuvant MA.17 trial, a signiﬁcantly higher
incidence of arthralgia and myalgia with letrozole relative to
placebo was seen in women who had received a full course
(4.5−6.0 years) of tamoxifen therapy (Table 2)[ 24]. The
incidence of arthritis was not signiﬁcantly diﬀerent between
the two groups (6% versus 5%; P = .07).
Taken together, these studies suggest that the profound
suppression of estrogen by AIs in postmenopausal women
c a nr e s u l ti na ne x a c e r b a t i o no fm e n o p a u s a ls y m p t o m s
and the emergence of musculoskeletal AEs, both in the
initial adjuvant setting and in those who have received
prior tamoxifen treatment. Despite these ﬁndings, however,
clinicaltrialsofAIshavefailedtoﬁndasigniﬁcantworsening
in QoL measures for patients on AIs relative to tamoxifen
or placebo, suggesting no apparent measurable impact on
day-to-day function and activity, even if patients were
experiencing musculoskeletal symptoms while on AIs [32–
35].
5.AI-RelatedMusculoskeletalSymptoms in
ClinicalPractice
Evidence from patient-perspective studies indicate that joint
aches are among the most troublesome symptoms for
patients taking AIs. In a large study of AI-related side eﬀects
(N = 612), the most commonly reported side eﬀects were
joint-related (joint pain, arthritis, and stiﬀness), and the AI
discontinuationratewas30%,with84%ofthesepatientsdis-
continuing therapy primarily because of joint-related symp-
toms [12]. Another recent cross-sectional study examined
the incidence of joint symptoms in postmenopausal women
(N = 200) receiving AI treatment for breast cancer (64%
anastrozole, 19% letrozole, 17% exemestane) [10]. These
investigators found a 47% incidence of AI-related joint pain,
while 23.5% reported a worsening of preexistent joint pain.
Similarly, 44% of patients in this study reported AI-related
joint stiﬀness, 26.5% reported new-onset joint stiﬀness, and
17.5% reported a worsening of baseline joint stiﬀness after
starting AI treatment. Symptoms were considered severe in
20%−25%ofthepatients.Asmallerstudyofpatientsoutside
of clinical trials receiving AIs (N = 56) found new or
worsening symptoms in 61% of the patients, with a severity
of 7.5 on a 10-point scale; notably, 30% rated their pain as
8−10, and the discontinuation rate was 20% for arthralgia
[11]. There was no apparent relation between arthralgia and
age or duration of AI use. Findings from these studies thus
suggest a higher “real-life” occurrence of musculoskeletal
symptoms with AI use than that observed in randomized
adjuvant trials (between 4% and 35%), and identify these
symptomsasimportantcausesoftreatmentdiscontinuation;
this can lead to a corresponding decrease in eﬃcacy and a
potential negative impact on breast cancer outcomes.
6.ManagingAI-InducedArthralgia
A temporal relationship between new-onset pain or the
worsening of preexisting pain and the initiation of an AI
makesthediagnosisofAI-relatedarthralgiaormyalgiarather
straightforward.Onphysicalexamination,thereisabsenceof
the inﬂammatory ﬁndings typical of arthritis [13]. Patients
should be reassured that their symptoms are not due to
permanent changes in the joints or joint destruction and are
reversible upon AI withdrawal, that the exacerbation of joint
symptoms may be a surrogate marker of the eﬀectiveness of
the hormonal therapy and may be associated with a reduced
risk of breast cancer recurrence [28], and that the symptoms
will likely improve with time. The strategies outlined below
may be useful to consider in the management of joint
symptoms.
6.1. Over-the-Counter (OTC) Pain Relievers. OTC pain
medications, including acetaminophen and ibuprofen, are
eﬀective therapies for minor arthralgia and myalgia symp-
toms and are appropriate initial therapies for symptoms of
acute joint pain [36]. Many women receiving AI therapy
may opt for these medications in lieu of discontinuing
hormonal treatment. In a cross-sectional study of arthralgias
secondary to AIs, a little more than half of the women with
AI-induced arthralgias used pain medicines [10]. NSAIDs
and acetaminophen were the most commonly used OTC
medications (82%). A minority of women (7%) required
more potent opiate medications for pain relief. Nearly 80%
of patients taking oral medications reported moderate to
complete relief of their arthralgia symptoms [10].
6.2. Switching to an Alternative Endocrine Therapy. Switch-
ing between endocrine therapies may be another option
for patients whose symptoms are troublesome, persistent,Journal of Oncology 5
and/or not eﬀectively managed with OTC pain medications.
One such strategy involves switching to another AI. This
option may be preferable for many patients, as the superior
eﬃcacy in preventing recurrence with AIs over tamoxifen is
retained.
The impact of the nonsteroidal AIs (letrozole and
anastrozole) on joint pain and stiﬀness was examined in a
randomized adjuvant trial [37]. There were no signiﬁcant
diﬀerences in the frequency or grade of joint symptoms
between letrozole and anastrozole; signiﬁcantly fewer joint
symptoms were reported with tamoxifen than with either
letrozole (P = .0192) or anastrozole (P = .0126), and three
quarters of patients who experienced joint symptoms while
on an AI did not have the same problems on tamoxifen.
Notably, more than half of the patients with symptoms on
one AI did not have the same problems on the other AI,
suggestingthatswitchingtherapiescouldimprovesymptoms
for some patients [37]. In the 6-month prospective, open-
label articular tolerance of letrozole (ATOLL) study, patients
(N = 179) who experienced severe joint pain requiring dis-
continuation while on anastrozole were switched to letrozole
[38].Patientswereinitiatedonletrozolefollowinga1-month
washout period. At the end of the 6-month followup, 71.5%
of the patients remained on letrozole electively, while 28.5%
of the patients discontinued because of severe joint pain; the
mostcommonlyaﬀectedjointswerethehands,knees,ankles,
and spine. Patients had been on prior anastrozole for a mean
of 14.6 months, and the duration of prior anastrozole was
the only signiﬁcant predictor of letrozole discontinuation
identiﬁed, such that a shorter duration of prior anastrozole
was associated with a higher risk of letrozole discontinuation
(P = .04). Age, menopause duration, sociodemographic
status,andpreviousosteoarthritishadnoimpact[38].Fewer
women overall reported arthralgia after switching (87%
versus 74%), and this was observed uniformly across all
aﬀected joints. Brief Pain Inventory scores also decreased
signiﬁcantly after the switch to letrozole (P<. 001), and QoL
measures were signiﬁcantly improved [38]. These results
suggest that in this setting, switching from anastrozole to
letrozole allows a sizable proportion of patients to continue
to receive the beneﬁts of more eﬀective AI therapy while
alleviating joint symptoms.
6.3. Nonpharmacologic Approaches. Simple, low-cost, or no-
cost lifestyle changes have been suggested to improve
women’s bone health and reduce the risk for osteoporosis.
These changes include increased physical activity, load-
bearing exercises, smoking cessation, and the avoidance of
excessive alcohol and caﬀeine [39]. The same measures may
beusefultowomendealingwithAI-associatedarthralgiaand
myalgia, although there are no conclusive data to prove their
eﬀectiveness. Other nonpharmacologic approaches include
weight loss, physical or occupational therapy, and targeted
heat therapy (e.g., heat packs or hot showers) [40].
6.4. Glucosamine. One small series (N = 56) has reported
the eﬃcacy of glucosamine in 15% of patients with AI-
related arthralgia and/or bone pain [11]. Glucosamine may
be a useful alternative therapy to reduce pain and improve
function in patients with osteoarthritis, although there are
no deﬁnitive data or recommendations regarding dosing or
the eﬃcacy of one preparation over another [41]. Moreover,
we are unaware of any controlled trials of glucosamine
speciﬁcally for the treatment of patients with AI-induced
arthralgia.
6.5. Acupuncture. A single-arm feasibility trial has been
conducted to determine whether electroacupuncture of
aﬀected joints (twice weekly for 2 weeks, followed by once
weekly for 6 weeks) could reduce pain and stiﬀness in
patients with AI-related arthralgia [42]. Using the brief joint
symptom inventory assessment, signiﬁcant improvement
frombaselineinjointpainseverity(P<. 0001),jointstiﬀness
(P<. 0001), and joint functional symptom interference
(P = .0001) were observed with the intervention. The
procedure was well-tolerated, and there was also signiﬁcant
improvement in fatigue (P = .005) and anxiety (P = .014)
end points examined [42]. Although requiring conﬁrmation
in a randomized controlled trial, this study demonstrates
the feasibility of this method to control AI-related arthralgia
without discontinuating AI therapy [42].
6.6. Vitamin D Supplementation and Joint Pain from AIs.
Vitamin D deﬁciency is associated with a syndrome of
musculoskeletal symptoms with generalized nonspeciﬁc
musculoskeletalpainandstiﬀness,aswellasimpairedmuscle
strength and function that is similar to that induced by AI
therapy. Hypovitaminosis D has been suggested as an under-
lying etiology in individuals with persistent, nonspeciﬁc
musculoskeletal pain [43]. In addition to musculoskeletal
symptoms, vitamin D deﬁciency has been implicated in
accelerated bone loss in women with breast cancer receiving
AI therapy [44]. A possible biologic explanation of AI-
induced musculoskeletal symptoms and their improvement
with vitamin D supplementation is that reduction in joint
estrogenlevelsmayunmasksubclinicalVitaminDdeﬁciency.
Estrogen increases activity of 1-alpha hydroxylase responsi-
ble for conversion of 25OHD to the biologically active 1,25-
dihydroxyvitamin D [45, 46]. In addition estrogen increases
expression of the Vitamin D receptor and VDR gene via
activation of ERK 1/2 signaling pathway [47, 48]. Increasing
vitamin D substrate via higher doses may increase the active
hormone 1,25-dihydroxyvitamin D with resultant reduction
in joint symptoms.
We conducted a pilot study to assess the prevalence of
suboptimal vitamin D levels in 60 women initiating adjuvant
letrozole for breast cancer, and to determine whether supple-
mentationwith50,000IUofvitaminD3weeklycouldreduce
musculoskeletal symptoms in women with suboptimal vita-
min D levels [49]. Baseline 25OHD levels were obtained,
and women were started on letrozole. Four weeks later,
women with baseline 25OHD levels ≤40ng/mL were started
on vitamin D3 supplementation of 50,000IU per week. At
week 16, after 12 weeks on high-dose vitamin D, 25OHD
levels were measured. Disability from joint pain was assessed
using the validated HealthAssessment Questionnaire (HAQ)6 Journal of Oncology
II at baseline and at week 16. We found that at baseline,
63% of women exhibited vitamin D deﬁciency (<20ng/mL)
or insuﬃciency (20–31ng/mL). 25OHD levels >40ng/mL
were achieved in all 42 subjects who received 12 weeks of
supplementation with 50,000IU vitamin D3 weekly, with no
adverse eﬀects. Our results also showed that 50,000IU of
vitamin D3, when given weekly to postmenopausal women
starting adjuvant AI therapy, resulted in clinically signiﬁcant
improvement in disability from joint symptoms. After 16
weeks of letrozole, HAQ II scores were better in women
whose 25OHD levels were above versus below the median
of 66ng/mL (P = .008, Mann-Whitney test). In addition,
more women with 25OHD levels >66ng/mL (median level)
reported no disability from joint pain than did women
with levels <66ng/mL (52 versus 19%; P = .026). We
concluded that vitamin D deﬁciency and insuﬃciency were
prevalent in postmenopausal women initiating adjuvant AI.
Vitamin D3 supplementation with 50,000 IU per week
was safe, signiﬁcantly increased 25OHD levels, and reduced
disability from AI-induced arthralgias. A randomized trial to
conﬁrm suggestions of a vitamin D protective eﬀect against
AI-associated disability from joint pain is underway (see
clinicaltrials.gov NCT00867217). Interestingly, our results
contrast with those of Dizdar et al., who found signiﬁcantly
higher levels of 25OHD in patients receiving AIs with
arthralgia symptoms versus those without symptoms (P =
.001) or control patients not receiving AIs (P = .005) [16].
Diﬀerences in supplementation among the groups studied
may have accounted for these ﬁndings, however, and no
conclusions regarding the impact on arthralgia were made
in the study.
7. Conclusions
Musculoskeletal symptoms are frequent in women treated
with AIs and may adversely aﬀect compliance with this class
of medications. The major clinical trials of the AIs have been
inconsistent in reporting musculoskeletal events and have
likely underestimated the incidence, in view of the ﬁndings
from clinical practice. In addition, the evaluation of joint
symptoms remains largely subjective, and there is a need for
more standardized assessments. Further research is needed
to understand the exact mechanism and pathophysiology
o ft h i ss i d ee ﬀect. To date, there are no proven treatment
interventions.EarlydataonvitaminDsupplementationlook
promising, and results from a larger, ongoing phase III trial
are awaited.
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